Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
Clene (NASDAQ: CLNN) reported its full year 2024 financial results and key operational updates. The company plans to submit a New Drug Application (NDA) for CNM-Au8® in ALS treatment during the second half of 2025 under the accelerated approval pathway. Key financial highlights include cash position of $12.2 million as of December 31, 2024, and a new $10.0 million debt facility secured at a lower interest rate.
The company reported a net loss of $39.4 million ($5.67 per share) for 2024, compared to $49.5 million ($9.43 per share) in 2023. Research and development expenses decreased to $20.1 million from $26.7 million, while general and administrative expenses reduced to $13.3 million from $14.4 million.
Clinical developments include plans to initiate the confirmatory Phase 3 RESTORE-ALS trial in mid-2025. The company is analyzing biomarker NfL data from its NIH-sponsored Early Access Protocol to support FDA requirements. Survival analysis showed a 4.1-month improvement in overall survival, with enhanced benefits observed in severe ALS patients.
Clene (NASDAQ: CLNN) ha riportato i risultati finanziari dell'intero anno 2024 e aggiornamenti operativi chiave. L'azienda prevede di presentare una Domanda di Nuovo Farmaco (NDA) per CNM-Au8® nel trattamento della SLA nella seconda metà del 2025 attraverso la procedura di approvazione accelerata. Le principali evidenze finanziarie includono una posizione di liquidità di 12,2 milioni di dollari al 31 dicembre 2024 e un nuovo finanziamento di debito di 10,0 milioni di dollari garantito a un tasso di interesse più basso.
L'azienda ha riportato una perdita netta di 39,4 milioni di dollari (5,67 dollari per azione) per il 2024, rispetto a 49,5 milioni di dollari (9,43 dollari per azione) nel 2023. Le spese per ricerca e sviluppo sono diminuite a 20,1 milioni di dollari da 26,7 milioni, mentre le spese generali e amministrative sono scese a 13,3 milioni di dollari da 14,4 milioni.
Gli sviluppi clinici includono piani per avviare il trial confermativo di Fase 3 RESTORE-ALS a metà del 2025. L'azienda sta analizzando i dati sui biomarcatori NfL provenienti dal suo Protocollo di Accesso Anticipato sponsorizzato dal NIH per supportare i requisiti della FDA. L'analisi di sopravvivenza ha mostrato un miglioramento di 4,1 mesi nella sopravvivenza complessiva, con benefici migliorati osservati nei pazienti con SLA severa.
Clene (NASDAQ: CLNN) informó sus resultados financieros del año completo 2024 y actualizaciones operativas clave. La compañía planea presentar una Solicitud de Nuevo Medicamento (NDA) para CNM-Au8® en el tratamiento de la ELA durante la segunda mitad de 2025 bajo la vía de aprobación acelerada. Los aspectos financieros clave incluyen una posición de efectivo de 12,2 millones de dólares al 31 de diciembre de 2024 y una nueva línea de crédito de 10,0 millones de dólares asegurada a una tasa de interés más baja.
La compañía reportó una pérdida neta de 39,4 millones de dólares (5,67 dólares por acción) para 2024, en comparación con 49,5 millones de dólares (9,43 dólares por acción) en 2023. Los gastos de investigación y desarrollo disminuyeron a 20,1 millones de dólares desde 26,7 millones, mientras que los gastos generales y administrativos se redujeron a 13,3 millones de dólares desde 14,4 millones.
Los desarrollos clínicos incluyen planes para iniciar el ensayo confirmatorio de Fase 3 RESTORE-ALS a mediados de 2025. La compañía está analizando datos de biomarcadores NfL de su Protocolo de Acceso Anticipado patrocinado por los NIH para cumplir con los requisitos de la FDA. El análisis de supervivencia mostró una mejora de 4,1 meses en la supervivencia general, con beneficios mejorados observados en pacientes con ELA severa.
클리니(나스닥: CLNN)은 2024년 전체 연도 재무 결과와 주요 운영 업데이트를 보고했습니다. 이 회사는 2025년 하반기에 ALS 치료를 위한 CNM-Au8®의 신약 신청(NDA)을 가속 승인 경로에 따라 제출할 계획입니다. 주요 재무 하이라이트에는 2024년 12월 31일 기준으로 1,220만 달러의 현금 보유액과 더 낮은 이자율로 확보된 1,000만 달러의 새로운 부채 시설이 포함됩니다.
회사는 2024년 3940만 달러의 순손실 (주당 5.67달러)을 기록했으며, 이는 2023년의 4950만 달러 (주당 9.43달러)와 비교됩니다. 연구 및 개발 비용은 2670만 달러에서 2010만 달러로 감소했으며, 일반 및 관리 비용은 1440만 달러에서 1330만 달러로 줄어들었습니다.
임상 개발에는 2025년 중반에 확인 시험인 3상 RESTORE-ALS를 시작할 계획이 포함됩니다. 이 회사는 FDA 요구 사항을 지원하기 위해 NIH가 후원하는 조기 접근 프로토콜에서 NfL 바이오마커 데이터를 분석하고 있습니다. 생존 분석 결과, 전체 생존 기간이 4.1개월 개선되었으며, 중증 ALS 환자에서 더 향상된 혜택이 관찰되었습니다.
Clene (NASDAQ: CLNN) a annoncé ses résultats financiers pour l'année complète 2024 et des mises à jour opérationnelles clés. La société prévoit de soumettre une Demande de Nouveau Médicament (NDA) pour CNM-Au8® dans le traitement de la SLA au cours de la deuxième moitié de 2025 dans le cadre de la procédure d'approbation accélérée. Les principaux points financiers incluent une position de liquidités de 12,2 millions de dollars au 31 décembre 2024 et une nouvelle facilité de crédit de 10,0 millions de dollars obtenue à un taux d'intérêt plus bas.
La société a déclaré une perte nette de 39,4 millions de dollars (5,67 dollars par action) pour 2024, contre 49,5 millions de dollars (9,43 dollars par action) en 2023. Les dépenses de recherche et développement ont diminué à 20,1 millions de dollars contre 26,7 millions, tandis que les dépenses générales et administratives ont été réduites à 13,3 millions de dollars contre 14,4 millions.
Les développements cliniques incluent des plans pour initier l'essai confirmatoire de Phase 3 RESTORE-ALS à la mi-2025. La société analyse les données sur les biomarqueurs NfL provenant de son protocole d'accès précoce sponsorisé par les NIH pour répondre aux exigences de la FDA. L'analyse de survie a montré une amélioration de 4,1 mois de la survie globale, avec des bénéfices améliorés observés chez les patients atteints de SLA sévère.
Clene (NASDAQ: CLNN) hat die finanziellen Ergebnisse für das gesamte Jahr 2024 und wichtige betriebliche Updates veröffentlicht. Das Unternehmen plant, im zweiten Halbjahr 2025 einen Antrag auf Zulassung eines neuen Arzneimittels (NDA) für CNM-Au8® zur Behandlung von ALS im Rahmen des beschleunigten Genehmigungsverfahrens einzureichen. Wichtige finanzielle Höhepunkte sind eine Liquiditätsposition von 12,2 Millionen Dollar zum 31. Dezember 2024 und eine neue Kreditfazilität in Höhe von 10,0 Millionen Dollar, die zu einem niedrigeren Zinssatz gesichert wurde.
Das Unternehmen berichtete von einem Nettoverlust von 39,4 Millionen Dollar (5,67 Dollar pro Aktie) für 2024, verglichen mit 49,5 Millionen Dollar (9,43 Dollar pro Aktie) im Jahr 2023. Die Forschungs- und Entwicklungskosten sanken auf 20,1 Millionen Dollar von 26,7 Millionen Dollar, während die allgemeinen und Verwaltungskosten auf 13,3 Millionen Dollar von 14,4 Millionen Dollar zurückgingen.
Klinische Entwicklungen umfassen Pläne zur Einleitung der bestätigenden Phase-3-Studie RESTORE-ALS Mitte 2025. Das Unternehmen analysiert NfL-Biomarkerdaten aus seinem vom NIH unterstützten Frühzugangsprotokoll, um die Anforderungen der FDA zu unterstützen. Die Überlebensanalyse zeigte eine Verbesserung der Gesamtüberlebenszeit um 4,1 Monate, wobei bei schweren ALS-Patienten verbesserte Vorteile beobachtet wurden.
- Secured new $10.0 million debt facility at better terms
- Demonstrated 4.1-month overall survival improvement in ALS patients
- Showed 11.9-month survival gain in severe ALS patients with 44% decreased mortality risk
- Reduced net loss to $39.4M in 2024 from $49.5M in 2023
- No significant safety concerns identified in over 800 patient years of CNM-Au8 use
- Cash runway only extends into Q2 2025
- Continued net losses of $39.4 million in 2024
- 65% of new debt is convertible, potentially leading to future dilution
- NDA submission timeline pushed to second half of 2025
- Additional FDA-requested data analysis required before NDA submission
Insights
Clene's 2024 financial results highlight both progress and challenges for this late-stage biopharmaceutical company. The net loss of $39.4 million (
The company's cash position is concerning. With only
The convertible note structure (65% convertible at
The critical inflection point for Clene appears to be the Q2 2025 FDA meeting regarding their biomarker analysis plan. A positive outcome could improve financing options, while setbacks could exacerbate funding challenges. The 12-month interest-only period on the new debt provides temporary relief, but the company will need additional capital before any potential commercial revenue materializes.
Clene's regulatory strategy is taking concrete shape with the FDA providing written guidance on a potential accelerated approval pathway for CNM-Au8 in ALS. The company's plan to leverage neurofilament light chain (NfL) as a surrogate biomarker represents a scientifically sound approach, as NfL is increasingly recognized as an important marker of neurodegeneration.
The survival data is particularly noteworthy. Overall survival improvement of 4.1 months (95% CI: 3 to 245 days, p=0.045) in the general patient population is statistically significant but modest. However, the enhanced survival benefit of 11.9 months in more severe ALS patients (those with elevated baseline NfL) with a
The FDA's indication that NfL could serve as a "reasonably likely surrogate endpoint" is crucial, as it opens the accelerated approval pathway. However, the agency maintains discretion on whether the magnitude of NfL change is predictive of clinical benefit. The planned Q2 2025 FDA meeting to finalize the statistical analysis plan for NfL biomarker evaluation will be pivotal.
The company's dual-track approach—pursuing NDA submission while simultaneously initiating the confirmatory Phase 3 RESTORE-ALS trial—is strategically sound. The safety profile of CNM-Au8 appears favorable, with no significant safety concerns identified across over 800 patient-years of exposure, strengthening its regulatory case. This positions Clene to potentially address a significant unmet need in ALS, though regulatory outcomes remain uncertain.
- Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALS
- Clene planning to initiate the confirmatory Phase 3 RESTORE-ALS trial in subjects with ALS in mid-2025
- Secured new
$10.0 million debt facility at a lower interest rate to replace remaining outstanding$7.85 million debt balance with Avenue Capital - Cash, cash equivalents and marketable securities of
$12.2 million as of December 31, 2024, includes$7.3 million in gross proceeds raised on October 1, 2024 - Clene collecting and analyzing biomarker NfL data from its large NIH-sponsored Early Access Protocol (EAP), for evaluation in the third quarter to satisfy the U.S. Food and Drug Administration (FDA) recommendation for additional neurofilament light chain (NfL) data
SALT LAKE CITY, March 24, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its full year 2024 financial results and provided recent operating highlights for the clinical programs in ALS and MS.
“We expect further regulatory guidance in 2025 on the critical next steps required to advance our CNM-Au8 NDA submission for the treatment of ALS under the accelerated approval pathway. We plan to meet with the agency in the second quarter of 2025 to align on our statistical analysis plan for our NfL biomarker data being collected from the ongoing NIH-sponsored EAP in ALS patients and then conduct the resulting analyses in the third quarter,” said Rob Etherington, President and CEO of Clene. “Our goal from these additional analyses is to determine concordance of the NIH-sponsored EAP NfL data with NfL results in our HEALEY Platform Trial. We intend to use this NfL surrogate biomarker data as a basis to file our NDA in the second half of 2025 for potential Accelerated Approval. In addition, Clene continues analyzing the long-term effect of CNM-Au8 on vision and cognition improvements seen in our VISIONARY-MS trial in MS. As always, we are incredibly motivated by our mission to help people suffering from ALS and other neurodegenerative diseases prolong their lifespan and improve their quality of life.”
Fourth Quarter 2024 and Recent Operating Highlights
CNM-Au8, a gold nanocrystal suspension, for the treatment of ALS
In December, Clene announced that it recently received written guidance from the Division of Neurology 1 (DN1), of the FDA regarding a potential accelerated approval pathway for CNM-Au8 in ALS.
- Following Clene’s November 1, 2024 meeting with DN1 and presentation of additional data and analyses, the FDA has provided guidance on a potential path to meet the regulatory standard for substantial evidence of effectiveness supporting accelerated approval. The FDA recommended that Clene investigate whether additional data from the ongoing EAPs could be leveraged to substantiate the effect of CNM-Au8 on NfL decline.
- Clene intends to follow the FDA’s recommendation to provide data from the ongoing EAPs and believes that it can address the FDA’s requests. Clene will meet with the FDA in the second quarter of 2025 to review and finalize its statistical analysis plan for the EAP NfL biomarker analyses followed by the actual NfL biomarker collection and analyses in the third quarter to support NDA submission. NDA submission is anticipated to occur in the second half of 2025. Additionally, the FDA indicated that the decision as to whether NfL can serve as a reasonably likely surrogate endpoint for the effects of CNM-Au8 in ALS and whether the magnitude of change observed on NfL in patients treated with CNM-Au8 is reasonably likely to predict clinical benefit for ALS would be a matter of FDA review.
- Clene completed new analyses comparing survival in participants who received CNM-Au8 30 mg (Regimen C) to those of Regimen A in the HEALEY ALS Platform Trial. Regimen A provided a large concurrent control group vs. CNM-Au8 treatment using the same randomization criteria established within the HEALEY master protocol. Long-term survival status, determined through public records and site reporting, was evaluated over a follow-up period of up to 48 months. Overall Survival Improvement (All-Cause Mortality) was observed with the covariate-adjusted restricted mean survival time (RMST) improvement of 4.1 months (
95% CI: 3 to 245 days, p=0.045). Further, enhanced survival benefit in more severe ALS seen in patients with baseline serum NfL > 33 pg/mL and TRICALS risk score range between –6.5 and –2.5 (i.e., filtering slow progressors where there was an imbalance between groups), where median survival improved by a 11.9 month gain and mortality risk in this subgroup decreased by44% (Cox HR: 0.556,95% CI: 0.367–0.842, p=0.006). - Clene plans to commence the confirmatory Phase 3 RESTORE-ALS trial with participant enrollment beginning in mid-2025 which is prior to the submission of the NDA. The study is designed to investigate the effects of CNM-Au8 on improved survival (primary endpoint) and delayed time to ALS clinical worsening events (secondary efficacy endpoint).
In over 800 patient years of use of CNM-Au8, no significant safety concerns or safety trends have been identified. No serious adverse events (SAEs) have been identified as related to CNM-Au8 treatment by any investigator to date.
Corporate Update
In December, Clene secured a new
Full Year 2024 Financial Results
Clene’s cash, cash equivalents and marketable securities totaled
Research and development expenses were
General and administrative expenses were
Total other expense was
Clene reported a net loss of
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
About CNM-Au8®
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is a federally registered trademark of Clene Nanomedicine Inc.
About RESTORE-ALS
RESTORE-ALS is a Phase 3 (RESTORE-ALS) confirmatory global, multi-center, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of CNM-Au8 in participants diagnosed with ALS on stable background therapy. The study is designed to investigate the effects of CNM-Au8 on improved survival (primary endpoint) and delayed time to ALS clinical worsening events (secondary efficacy endpoint). Participants will be randomized in a 2:1 ratio to receive either active treatment with CNM-Au8 30 mg or matched placebo daily during the 108-week double-blind treatment period.
The Phase 3 RESTORE-ALS clinical trial, due to launch in mid-2025, is planned to serve as the confirmatory clinical trial required to meet the FDA’s guidance for an “underway” clinical trial when a New Drug Application requesting Accelerated Approval is submitted.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Clene’s forward-looking statements include, but are not limited to, statements regarding the Company’s expectations regarding the timing of its Phase 3 RESTORE-ALS study, the submission of its NDA, its meeting with the FDA and resulting analyses, and the actual NfL biomarker collection and analyses; that it will be able to determine concordance of the NIH-sponsored EAP NfL data with NfL data from the HEALEY ALS Platform Trial; and that its resources will be sufficient to fund its operations into the second quarter of 2025. In addition, any statements that refer to characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. Some factors that could cause actual results to differ include the Company's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies; the Company’s limited operating history and its ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
| Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 | Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com 617-283-2856 |
CLENE INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
(Audited)
| Year Ended December 31, | |||||||
| 2024 | 2023 | ||||||
| Revenue: | |||||||
| Product revenue | $ | 237 | $ | 498 | |||
| Royalty revenue | 105 | 156 | |||||
| Total revenue | 342 | 654 | |||||
| Operating expenses: | |||||||
| Cost of revenue | 70 | 121 | |||||
| Research and development | 20,058 | 26,655 | |||||
| General and administrative | 13,307 | 14,418 | |||||
| Total operating expenses | 33,435 | 41,194 | |||||
| Loss from operations | (33,093 | ) | (40,540 | ) | |||
| Other income (expense), net: | |||||||
| Interest income | 865 | 1,389 | |||||
| Interest expense | (4,064 | ) | (4,558 | ) | |||
| Loss on extinguishment of notes payable | (214 | ) | — | ||||
| Commitment share expense | — | (402 | ) | ||||
| Issuance costs for common stock warrant liabilities | (157 | ) | (333 | ) | |||
| Loss on initial issuance of equity | (2,097 | ) | (14,840 | ) | |||
| Change in fair value of common stock warrant liabilities | (702 | ) | 6,337 | ||||
| Change in fair value of derivative liabilities | (379 | ) | — | ||||
| Change in fair value of Clene Nanomedicine contingent earn-out liability | 75 | 2,189 | |||||
| Change in fair value of Initial Stockholders contingent earn-out liability | 10 | 281 | |||||
| Research and development tax credits and unrestricted grants | 357 | 963 | |||||
| Other income (expense), net | (1 | ) | 10 | ||||
| Total other income (expense), net | (6,307 | ) | (8,964 | ) | |||
| Net loss before income taxes | (39,400 | ) | (49,504 | ) | |||
| Income tax expense | — | — | |||||
| Net loss | (39,400 | ) | (49,504 | ) | |||
| Other comprehensive loss: | |||||||
| Unrealized gain (loss) on available-for-sale securities | (1 | ) | 16 | ||||
| Foreign currency translation adjustments | (127 | ) | (20 | ) | |||
| Total other comprehensive loss | (128 | ) | (4 | ) | |||
| Comprehensive loss | $ | (39,528 | ) | $ | (49,508 | ) | |
| Net loss per share – basic and diluted | $ | (5.67 | ) | $ | (9.43 | ) | |
| Weighted average common shares used to compute basic and diluted net loss per share | 6,954,133 | 5,246,941 | |||||
CLENE INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Audited)
| December 31, | December 31, | ||||||
| 2024 | 2023 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 12,155 | $ | 28,821 | |||
| Marketable securities | — | 6,179 | |||||
| Accounts receivable | 64 | 143 | |||||
| Inventory | 68 | 37 | |||||
| Prepaid expenses and other current assets | 3,870 | 3,672 | |||||
| Total current assets | 16,157 | 38,852 | |||||
| Restricted cash | 58 | 58 | |||||
| Operating lease right-of-use assets | 3,643 | 4,168 | |||||
| Property and equipment, net | 7,479 | 9,263 | |||||
| TOTAL ASSETS | $ | 27,337 | $ | 52,341 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,240 | $ | 1,504 | |||
| Accrued liabilities | 7,766 | 3,720 | |||||
| Operating lease obligations, current portion | 926 | 576 | |||||
| Finance lease obligations, current portion | — | 27 | |||||
| Notes payable, current portion | 359 | 14,627 | |||||
| Convertible notes payable, current portion | — | 4,876 | |||||
| Total current liabilities | 10,291 | 25,330 | |||||
| Operating lease obligations, net of current portion | 4,132 | 4,903 | |||||
| Notes payable, net of current portion | 4,610 | 1,894 | |||||
| Convertible notes payable, net of current portion | 10,816 | 5,258 | |||||
| Common stock warrant liabilities | 4,541 | 1,481 | |||||
| Derivative liabilities | 1,804 | — | |||||
| Clene Nanomedicine contingent earn-out liability | — | 75 | |||||
| Initial Stockholders contingent earn-out liability | — | 10 | |||||
| TOTAL LIABILITIES | 36,194 | 38,951 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity (deficit): | |||||||
| Common stock, | 1 | 1 | |||||
| Additional paid-in capital | 273,194 | 255,913 | |||||
| Accumulated deficit | (282,123 | ) | (242,723 | ) | |||
| Accumulated other comprehensive income | 71 | 199 | |||||
| TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) | (8,857 | ) | 13,390 | ||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | $ | 27,337 | $ | 52,341 | |||
FAQ
When will Clene (CLNN) submit its NDA for CNM-Au8 in ALS treatment?
What were Clene's (CLNN) financial results for full year 2024?
What survival benefits did CNM-Au8 show in CLNN's ALS trials?
What new financing did CLNN secure in December 2024?
When will CLNN start the Phase 3 RESTORE-ALS trial?
